Research Axis 3: Development of new biomarkers and innovative personalized therapies

Thematic leaders: Mathilde Bonnet and Anthony Buisson
 

• Development of diagnostic tools.
  • Identification of noninvasive biomarkers to diagnose AIEC-colonized CD patients.
  • Predictive diagnosis of post-operative recurrence in CD patients, in relationship with AIEC status.
  • Colibactin-producing E. coli as a pronostic marker in CRC.
• Development of therapeutic approaches.
  • Impact of physical activity on microbiota composition and host susceptibility to pathobiont exposure in chronic diseases.
  • Development of anti-FimH molecules to block AIEC adhesion to intestinal epithelium.
  • Bacteriophages targeting AIEC.
  • Antagonist effects of probiotics against pathogenic and pathobiont E. coli.
  • Eradication of AIEC using antibiotherapy strategies.
  • Inhibition of the genotoxic action of the pks genomic island, which encodes the colibactin.
  • Develop global and/or more focused approaches based on specific bacterial virulent factors identified.